GlassScriptPhysician profile
Samyukta Mullangi
NPI 1598143497
$2,761.37
in general payments reported to CMS, 2019-2025
33 companies · $1,698 in 2025
The $1,698 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $246 · 2024: $817 · 2025: $1,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,577 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,576.93 |
| Education | $184.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $350.23 | 2023-2025 | Lynparza, Tagrisso, Enhertu |
| Novartis Pharmaceuticals Corporation | $300.94 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $257.03 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.65 | 2025 | |
| Glaxosmithkline, LLC. | $161.92 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $127.20 | 2024-2025 | Ninlaro, Alunbrig |
| Daiichi Sankyo INC. | $126.93 | 2023-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $119.52 | 2024-2025 | Opdivo, Opdualag, Krazati |
| Regeneron Healthcare Solutions, INC. | $117.34 | 2024-2025 | Libtayo |
| Janssen Biotech, INC. | $82.42 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $66.92 | 2024-2025 | |
| Eisai INC. | $65.50 | 2024-2025 | |
| Gilead Sciences, INC. | $63.05 | 2023-2024 | |
| Beigene USA, INC. | $60.40 | 2023-2025 | Tevimbra, Brukinsa |
| Alexion Pharmaceuticals, INC. | $55.84 | 2024-2025 | Ultomiris |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $54.51 | 2024-2025 | |
| Incyte Corporation | $53.02 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| Beone Medicines USA, INC. | $50.78 | 2025 | Tevimbra |
| Aveo Pharmaceuticals, INC. | $48.70 | 2023-2024 | Fotivda |
| Jazz Pharmaceuticals INC. | $47.29 | 2024 | |
| Celgene Corporation | $46.65 | 2023-2025 | Reblozyl |
| Sun Pharmaceutical Industries INC. | $36.56 | 2025 | |
| Lilly USA, LLC | $31.03 | 2024 | Verzenio |
| Astellas Pharma US INC | $30.66 | 2025 | Xtandi |
| Abbvie INC. | $29.60 | 2024-2025 | |
| Seagen INC. | $27.85 | 2023 | Tukysa |
| Legend Biotech USA INC. | $26.33 | 2025 | Carvykti |
| Array Biopharma INC | $21.73 | 2024 | Lorbrena, Braftovi |
| Emd Serono, INC. | $20.11 | 2025 | |
| Sobi, INC | $18.62 | 2025 | |
| Pharmaessentia USA Corporation | $16.78 | 2024 | Besremi |
| Genentech USA, INC. | $14.02 | 2024 | Tecentriq, Phesgo |
| Amgen INC. | $13.24 | 2023 | Nplate, Xgeva, Vectibix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samyukta Mullangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.